Why the study?
Restenosis is a severe complication after percutaneous transluminal coronary angioplasty that limits the long-term efficacy of the intervention.
Answers are grounded in this paper and cite their sources.
Exosomes derived from AT2R-overexpressing bone mesenchymal stem cells effectively prevent restenosis after carotid artery injury by attenuating neointimal hyperplasia in a rat model.
Restenosis is a severe complication after percutaneous transluminal coronary angioplasty which limits the long-term efficacy of the intervention. In this study, we investigated the efficiency of exosomes derived from AT2R-overexpressing bone mesenchymal stem cells on the prevention of restenosis after carotid artery injury. Our data showed that AT2R-EXO promoted the proliferation and migration of vascular endothelial cells and maintained the ratio of eNOS/iNOS. On the contrary, AT2R-EXO inhibited the proliferation and migration of vascular smooth muscle cells. In vivo study proved that AT2R-Exo were more effectively accumulated in the injured carotid artery than EXO and Vehicle-EXO controls. AT2R-EXO treatment could improve blood flow of the injured carotid artery site more effectively. Further analysis revealed that AT2REXO prevents restenosis after carotid artery injury by attenuating the injury-induced neointimal hyperplasia. Our study provides a novel and more efficient exosome for the treatment of restenosis diseases after intervention.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: